Electromagnetic treatment apparatus and method for angiogenesis modulation of living tissues and cells

• US 8,415,123 B2
• Filed: 03/15/2010
• Issued: 04/09/2013
• Est. Priority Date: 04/19/2004
• Status: Active Grant

• Current Assignee: SofPulse, Inc.
• Original Assignee: Ivivi Health Sciences, LLC
• Inventors: Pilla, Arthur A., DiMino, Andre A.
• Primary Examiner(s): Ketter, Jim
• Application Number:
  US12/661,377
• Publication Number:
  US 20100179373A1
• Time in Patent Office: 1,121 Days
• Field of Search: None
• US Class Current: 435/173.1
• CPC Class Codes: A61N 1/40 Applying electric fields by inductive or capacitive coupling microwave apparatus A61N5/00; Applying radio-frequency signals
• CPC Class Codes: A61N 2/02 using magnetic fields produced by coils, including single turn loops or electromagnets A61N2/12 takes precedence
• CPC Class Codes: C12M 35/02 Electrical or electromagnetic means, e.g. for electroporation or for cell fusion
• CPC Class Codes: C12N 13/00 Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

Abstract

An apparatus and method for electromagnetic treatment of living tissues and cells comprising: configuring at least one waveform according to a mathematical model having at least one waveform parameter, said at least one waveform to be coupled to a angiogenesis and neovascularization target pathway structure; choosing a value of said at least one waveform parameter so that said at least waveform is configured to be detectable in said angiogenesis and neovascularization target pathway structure above background activity in said target pathway structure; generating an electromagnetic signal from said configured at least one waveform; and coupling said electromagnetic signal to said angiogenesis and neovascularization target pathway structure using a coupling device.

Claims

1. A method for electromagnetic treatment of living tissues and cells by enhancing angiogenesis and neovascularization comprising the steps of:

applying a portable electromagnetic treatment device adjacent to a target tissue site;

generating an electromagnetic signal from at least one waveform; and

coupling said electromagnetic signal to said angiogenesis and neovascularization target pathway structure using a coupling device; and

inducing an electromagnetic field at the target tissue site from the at least one waveform, wherein said at least one waveform is configured to be coupled to an angiogenesis and neovascularization target pathway structure at the target tissue site by modulating binding of calcium to Calmodulin, wherein the waveform induces a power that is greater than the thermal noise power of calcium binding to Calmodulin so that the at least one waveform is configured to be detectable in said angiogenesis and neovascularization target pathway structure above background activity in said angiogenesis and neovascularization target pathway structure.

2. The method of claim 1, wherein said at least one waveform comprises at least one of a frequency component parameter that configures said at least one waveform to repeat between about 0.01 Hz and about 100 MHz, a burst amplitude envelope parameter that follows a mathematically defined amplitude function, a burst width parameter that varies at each repetition according to a mathematically defined width function, a peak induced electric field parameter varying between about 1 μ

V/cm and about 100 mV/cm in said target pathway structure according to a mathematically defined function, and a peak induced magnetic field parameter varying between about 1 and about 0.1 T in said target pathway structure according to a mathematically defined function.

3. The method of claim 1, wherein said angiogenesis and neovascularization target pathway structure includes the binding of at least one of ions and ligands.

4. The method of claim 1, wherein said inducing an electromagnetic field at the target tissue site comprises modulating growth factor production in living cells and tissues.

5. The method of claim 1, wherein said inducing an electromagnetic field at the target tissue site comprises modulating cytokine production in living cells and tissues.

6. The method of claim 1, wherein said inducing an electromagnetic field at the target tissue site comprises modulating growth factors and cytokines relevant to angiogenesis and neovascularization.

7. The method of claim 1, wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment of bone fractures and disorders.

8. The method of claim 1, wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment of cardiovascular diseases.

9. The method of claim 1, wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment of cerebral diseases.

10. The method of claim 1, wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment of cerebrovascular disease.

11. The method of claim 1, wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment peripheral vascular disease.

12. The method of claim 1, wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment of diseased or ischemic cells and tissues.

13. The method of claim 1, wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment of an acute or chronic soft tissue wound.

14. The method of claim 1, wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment of sprains strains and contusions.

15. The method of claim 1, wherein the at least one waveform comprises frequency components for coupling to an impedance of the binding of calcium to Calmodulin and thus the angiogenesis and neovascularization target pathway.

16. The method of claim 15, wherein the at least one waveform comprises frequency components that fall within the bandpass of the kinetics of binding of calcium to Calmodulin.

17. The method of claim 1, wherein generating the electromagnetic signal comprises generating a burst of arbitrary waveforms having a plurality of frequency components ranging from about 0.01Hz to about 100 MHz, the plurality of frequency components satisfying a SNR or PSNR model for the angiogenesis and neovascularization target pathway structure.

18. The method of claim 1, wherein the induced electromagnetic field comprises a burst duration between about 10 msec to about 100 msec.

19. The method of claim 1, wherein the induced electromagnetic field comprises a peak amplitude between about 1 μ

V/cm and about 100 mV/cm.

20. The method of claim 1, wherein the at least one waveform has a frequency of approximately 27.12 MHz.

21. The method of claim 1, wherein generating the electromagnetic signal comprises applying a treatment regime so that the electromagnetic signal is applied according to the treatment regimen.

22. The method of claim 21, wherein the treatment regimen applies the electromagnetic signal for a total time of under 1 minute to 240 minutes daily.

23. The method of claim 1, wherein the electromagnetic signal comprises a duty cycle of between about 1 to about 10⁻

5.

24. A method for electromagnetic treatment of living tissues and cells by enhancing angiogenesis and neovascularization comprising the steps of:

applying a portable electromagnetic treatment device adjacent to a target tissue site;

generating an electromagnetic signal from at least one waveform; and

coupling said electromagnetic signal to said angiogenesis and neovascularization target pathway structure using a coupling device; and

inducing an electromagnetic field at the target tissue site from the at least one waveform, wherein said at least one waveform is configured to be coupled to an angiogenesis and neovascularization target pathway structure at the target tissue site, wherein the waveform is further configured to have a time constant that matches the bandpass of calcium binding to Calmodulin according to an electrically equivalent model of calcium binding to Calmodulin, and wherein the waveform is configured to induce a power at the target tissue that is greater than the thermal noise power of calcium binding to Calmodulin.